SCHEMBL18546196

SCHEMBL18546196

COc1cc(CCc2cccc(O)c2)cc(O)c1OC

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 4/20 0.63
TUBB P07437 4/20 0.63
TUBA3C P0DPH7 4/20 0.63
TUBA1B P68363 4/20 0.63
TUBA4A P68366 4/20 0.63
TUBB4B P68371 4/20 0.63
TUBB3 Q13509 4/20 0.63
TUBB2A Q13885 4/20 0.63
TUBB8 Q3ZCM7 4/20 0.63
TUBA3E Q6PEY2 4/20 0.63
TUBA1A Q71U36 4/20 0.63
TUBA1C Q9BQE3 4/20 0.63
TUBB6 Q9BUF5 4/20 0.63
TUBB2B Q9BVA1 4/20 0.63
TUBB1 Q9H4B7 4/20 0.63
CALM1 P0DP23 2/20 0.59
GABRA1 P14867 1/20 0.59
GABRG2 P18507 1/20 0.59
GABRB3 P28472 1/20 0.59
GABRA3 P34903 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29934781 1.00 TUBB4A (0.63) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL30008021 1.00 TUBB4A (0.63) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL29449679 1.00 TUBB4A (0.63) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL9089602 0.92 CALM1 (0.64) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL20682611 0.88 POLB (0.68) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL18563067 0.84 CALM1 (0.66) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL30007868 0.84 CALM1 (0.66) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL30079962 0.84 TUBB4A (0.74) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL29286367 0.84 TUBB4A (0.74) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL11504708 0.83 TUBB4A (0.69) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022236789-A1 EXTRACT OF DENDROBIUM SINENSE, DENDROBIUM DENSIFLORUM, OR DENDROBIUM BENSONIAE, AND APPLICATION OF MAIN COMPONENTS THEREOF AS ANTI-INFLAMMATORY FORMULATION 中国热带农业科学院热带生物技术研究所 2022-11-17 WO claimed
CN-113633718-A Extract of Dendrobium huoshanense, Dendrobii florida or Dendrobium nobile and application of main component of extract as anti-inflammatory preparation 中国热带农业科学院热带生物技术研究所 2021-11-12 CN claimed
WO-2022236789-A1 EXTRACT OF DENDROBIUM SINENSE, DENDROBIUM DENSIFLORUM, OR DENDROBIUM BENSONIAE, AND APPLICATION OF MAIN COMPONENTS THEREOF AS ANTI-INFLAMMATORY FORMULATION 中国热带农业科学院热带生物技术研究所 2022-11-17 WO disclosed
WO-2022236789-A1 EXTRACT OF DENDROBIUM SINENSE, DENDROBIUM DENSIFLORUM, OR DENDROBIUM BENSONIAE, AND APPLICATION OF MAIN COMPONENTS THEREOF AS ANTI-INFLAMMATORY FORMULATION 中国热带农业科学院热带生物技术研究所 2022-11-17 WO disclosed
CN-109952286-B Skin protection composition based on dendrobe components 香港浸会大学 2022-03-22 CN disclosed
CN-113633718-A Extract of Dendrobium huoshanense, Dendrobii florida or Dendrobium nobile and application of main component of extract as anti-inflammatory preparation 中国热带农业科学院热带生物技术研究所 2021-11-12 CN disclosed
CN-110698328-A Method for using dihydroresveratrol or stilbene derivatives and/or chemical variants thereof as antimicrobial agents 香港浸会大学 2020-01-17 CN disclosed
US-10351500-B2 Method of using of dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants as antimicrobial agents HONG KONG BAPTIST UNIVERSITY (HK) 2019-07-16 US disclosed
CN-109952286-A Skin protection composition based on Dendrobium ingredient 香港浸会大学 2019-06-28 CN disclosed
US-10188590-B2 Skin-protection composition containing Dendrobium-based ingredients HONG KONG BAPTIST UNIVERSITY (HK) 2019-01-29 US disclosed
US-10017442-B2 Method of using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatment of tumorous pathologies HONG KONG BAPTIST UNIVERSITY (HK) 2018-07-10 US disclosed
US-20170290782-A1 Method of Using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatments of fibrotic and diabetic conditions HONG KONG BAPTIST UNIVERSITY (HK) 2017-10-12 US disclosed
US-20170290782-A1 Method of Using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatments of fibrotic and diabetic conditions HONG KONG BAPTIST UNIVERSITY (HK) 2017-10-12 US disclosed
US-9738581-B2 Method of using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatments of fibrotic and diabetic conditions HONG KONG BAPTIST UNIVERSITY (HK) 2017-08-22 US disclosed
US-9738581-B2 Method of using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatments of fibrotic and diabetic conditions HONG KONG BAPTIST UNIVERSITY (HK) 2017-08-22 US disclosed
US-20170057896-A1 Method of Using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatments of fibrotic and diabetic conditions HONG KONG BAPTIST UNIVERSITY 2017-03-02 US disclosed
US-20170057906-A1 SKIN-PROTECTION COMPOSITION CONTAINING DENDROBIUM-BASED INGREDIENTS HONG KONG BAPTIST UNIVERSITY 2017-03-02 US disclosed
US-20170057906-A1 SKIN-PROTECTION COMPOSITION CONTAINING DENDROBIUM-BASED INGREDIENTS HONG KONG BAPTIST UNIVERSITY 2017-03-02 US disclosed
US-20170057906-A1 SKIN-PROTECTION COMPOSITION CONTAINING DENDROBIUM-BASED INGREDIENTS HONG KONG BAPTIST UNIVERSITY 2017-03-02 US disclosed
US-20170057896-A1 Method of Using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatments of fibrotic and diabetic conditions HONG KONG BAPTIST UNIVERSITY 2017-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170057906-A1 SKIN-PROTECTION COMPOSITION CONTAINING DENDROBIUM-BASED INGREDIENTS TYR, MC1R, SYMPK TUBB4A 901/4885TUBB 575/4885TUBA3C 3824/4885
US-10017442-B2 Method of using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatment of tumorous pathologies VHL, ETV1, DHODH TUBB4A 2571/4885TUBB 3105/4885TUBA3C 3944/4885
US-10188590-B2 Skin-protection composition containing Dendrobium-based ingredients TYR, MC1R, SYMPK TUBB4A 1115/4885TUBB 729/4885TUBA3C 4087/4885
US-20170057896-A1 Method of Using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatments of fibrotic and diabetic conditions RNASE1, KRAS, DPP3 TUBB4A 3202/4885TUBB 4160/4885TUBA3C 3294/4885
US-10351500-B2 Method of using of dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants as antimicrobial agents DPM1, SUCLG1, VDR TUBB4A 383/4885TUBB 194/4885TUBA3C 903/4885
US-20170290782-A1 Method of Using dihydro-resveratrol or its stilbenoid derivatives and/or chemical variants in treatments of fibrotic and diabetic conditions RNASE1, IAPP, DPP4 TUBB4A 3710/4885TUBB 4432/4885TUBA3C 4265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.